Literature DB >> 23613013

Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn's registry.

E Fischer1, S Reuschl, M Quinkler, L C Rump, S Hahner, M Bidlingmaier, M Reincke.   

Abstract

Primary aldosteronism (PA) is the most frequent cause of secondary arterial hypertension. The aldosterone to renin ratio (ARR) is the gold standard for screening, but variability between biochemical methods used remains of concern. The aim of the study was to analyze center-specific features of biochemical diagnostic strategies prior to the 2008 consensus within the German Conn's Registry. The study was designed as a retrospective study in 5 tertiary care hospitals. Patients analyzed for PA between 1990 and 2006 were studied. Characteristics of the assays used to determine ARR during establishing the diagnosis of PA were analyzed in the retrospective part of the German Conn's Registry. Eighty-six out of 484 documented ARR values had to be excluded from further evaluations because the laboratory or the assays were unknown. In the remaining 398 patients ARR was determined using 10 different assay combinations in the centers (aldosterone plus plasma renin activity or concentration). Considerable differences were seen between the mean concentrations for aldosterone (p<0.0001), renin concentration (p<0.001), and renin activity (p=0.009) for the different assays. The differences between the absolute concentrations measured by the different assays also had significant impact upon the resulting mean ratios. If published cutoff values are applied, the use of different commercial assays to determine the ARR in clinical routine results in major differences in positive screening rates. This heterogeneity affects sensitivity and specificity of screening for PA. Our data emphasize the importance of standardized screening procedures, which must include standardization of biochemical methods. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23613013     DOI: 10.1055/s-0033-1343448

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

Review 1.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

Review 2.  Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.

Authors:  Peter J Fuller
Journal:  Clin Biochem Rev       Date:  2013-11

3.  Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers.

Authors:  Matthias B Moor; Nasser A Dhayat; Simeon Schietzel; Michael Grössl; Bruno Vogt; Daniel G Fuster
Journal:  Urolithiasis       Date:  2022-02-24       Impact factor: 2.861

4.  Age-Related Cutoffs of Plasma Aldosterone/Renin Concentration for Primary Aldosteronism Screening.

Authors:  Linqiang Ma; Ying Song; Mei Mei; Wenwen He; Jinbo Hu; Qingfeng Cheng; Ziwei Tang; Ting Luo; Yue Wang; Qianna Zhen; Zhihong Wang; Hua Qing; Yihong He; Qifu Li; Shumin Yang
Journal:  Int J Endocrinol       Date:  2018-07-16       Impact factor: 3.257

5.  A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable.

Authors:  Erik S Venos; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka; Gregory A Kline
Journal:  BMC Endocr Disord       Date:  2014-12-11       Impact factor: 2.763

6.  Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS.

Authors:  Carmina Teresa Fuss; Katharina Brohm; Max Kurlbaum; Anke Hannemann; Sabine Kendl; Martin Fassnacht; Timo Deutschbein; Stefanie Hahner; Matthias Kroiss
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.